Aphria (APHQF) has heavily focused on the medical cannabis market and continues to do so as we move towards the planned legalization of recreational cannabis in Canada on October 17, 2018. The company has supply agreements with Canadian provinces to supply cannabis for recreational purposes. To learn more about the product strategy of cannabis players (HMLSF) such as Canopy Growth (CGC) (WEED) and Aurora Cannabis (ACB)(ACBFF), read Finding the Right Cannabis Stock for Your Portfolio.
The overall consensus recommendation for Aphria is a “buy,” the same as last month. Three analysts maintained a “strong buy” recommendation, while four analysts maintained a “buy” recommendation on the stock in September as well. Consequently, one analyst maintained a “hold” recommendation on the stock as we can see in the above chart. None of the analysts have a “sell” on Aphria, which is usually not uncommon to see with these sell-side recommendations.
While the recommendation remained unchanged month-over-month, the price target rose from 22.9 Canadian dollars to 23.6 Canadian dollars in September. Aphria closed at 21.6 Canadian dollars on September 11, which implies a 9% upside over the current price target on the stock.
Next, we will discuss the Cronos Group (CRON).